文献速递肺外科

中心型小实性优势cN0非小细胞肺癌:肺段切除与肺叶切除的可行性与预后比较

Feasibility and comparative prognosis of segmentectomy versus lobectomy in centrally located small and solid dominant cN0 non-small cell lung cancer.
PubMed 文献 · J Thorac Cardiovasc Surg · 2024-07-03

该回顾性研究纳入1240例小且影像学实性优势cN0非小细胞肺癌患者,其中299例中心型肿瘤符合条件,比较肺段切除(n=121)与肺叶切除(n=178)的预后。结果显示两组无复发生存(RFS)和总生存(OS)无显著差异(P=.794和.577),倾向性评分匹配后肺门和纵隔淋巴结升级、局部区域复发及RFS、OS仍无显著差异。结论提示在适当选择的中心型、小(≤2 cm)且影像学实性优势NSCLC患者中,肺段切除可能是可行治疗选择,局部控制和预后与肺叶切除相当。

要点

  • 中心型、≤2 cm、影像学实性优势cN0 NSCLC患者中,肺段切除与肺叶切除的RFS和OS无显著差异。
  • 倾向性评分匹配后,两组肺门和纵隔淋巴结升级及局部区域复发无显著差异。
  • 倾向性评分调整的多变量Cox分析显示肺段切除不是RFS和OS的独立预后因素。

核心结论

  • 在适当选择的中心型、小(≤2 cm)且影像学实性优势cN0 NSCLC患者中,肺段切除可能是可行治疗选择,局部控制和预后与肺叶切除相当。

研究设计与样本

  • 回顾性研究,纳入2010年1月至2022年12月间接受肺叶切除或肺段切除的小且影像学实性优势cN0 NSCLC患者1240例,其中中心型肿瘤(位于肺实质内2/3)且符合条件者299例,采用倾向性评分匹配平衡两组基线特征。

主要发现

  • 299例 eligible 患者中,肺段切除组(n=121)与肺叶切除组(n=178)的RFS和OS无显著差异(P=.794和.577)。
  • 倾向性评分匹配后93例患者中,肺门和纵隔淋巴结升级无显著差异(P=1.00),局部区域复发在肺段切除组(n=4)与肺叶切除组(n=4)相当。
  • 匹配后两组RFS和OS仍无显著差异(P=.700和.870)。
  • 倾向性评分调整的多变量Cox分析显示,肺段切除不是RFS(HR 0.89,95%CI 0.43-1.85,P=.755)和OS(HR 1.09,95%CI 0.38-3.14,P=.860)的独立预后因素。

临床怎么用

  • 对于中心型、肿瘤大小≤2 cm且影像学实性优势的cN0 NSCLC患者,肺段切除可作为肺叶切除之外的可行选择,局部控制和预后与肺叶切除相当。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To determine the feasibility of segmentectomy in patients with central, whole tumor size ≤2 cm and radiologically solid-dominant cN0 non-small cell lung cancer (NSCLC). METHODS: We retrospectively reviewed 1240 patients who underwent lobectomy or segmentectomy for small and radiologically solid-dominant cN0 NSCLC between January 2010 and December 2022. The inclusion criteria encompassed centrally located tumors, defined as tumors located in the inner two-thirds of the pulmonary parenchyma. Propensity score matching was applied to balance the baseline characteristics in the 2 study groups. RESULTS: Among the 299 eligible patients, no significant differences in recurrence-free survival (RFS) and overall survival (OS) were observed between the segmentectomy (n = 121) and lobectomy (n = 178) groups (P = .794 and .577, respectively). After propensity score matching, no significant differences in hilar and mediastinal lymph node upstaging were found among the 93 matched patients (P = 1.00), and locoregional recurrence was comparable in the segmentectomy (n = 4) and lobectomy (n = 4) groups. RFS and OS did not differ significantly between the 2 groups (P = .700 and .870, respectively). Propensity score-adjusted multivariable Cox analysis for RFS and OS indicated that segmentectomy was not an independent prognostic factor (RFS: hazard ratio [HR], 0.89; 95% confidence interval [CI], 0.43-1.85; P = .755; OS: HR, 1.09; 95% CI, 0.38-3.14; P = .860). CONCLUSIONS: Segmentectomy may be a viable treatment option, with local control and prognosis comparable to that of lobectomy in appropriately selected patients with central, small (≤2 cm), and radiologically solid-dominant NSCLC.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Tsubokawa N, Mimae T, Saeki A, et al. Feasibility and comparative prognosis of segmentectomy versus lobectomy in centrally located small and solid dominant cN0 non-small cell lung cancer. J Thorac Cardiovasc Surg. 2024. PMID: 38969057. doi:10.1016/j.jtcvs.2024.06.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。